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Background:  Metabolic Syndrome (MS) is characterized by insulin resistance and increased cardiovascular risk. A commercially available 
nutraceutical combination (NC, an association of berberine 500 mg, red yeast rice 200 mg, and policosanol 10 mg) has been found to be effective 
at reducing blood cholesterol; subgroup analyses of a recent study also suggested a benefit on insulin resistance. Aim of this study was to test the 
effect of NC on insulin resistance in subjects with MS.
Methods:  59 patients with MS were randomly assigned to NC or placebo for 18 weeks, in a double-blind, placebo-controlled design. All patients 
received lifestyle and dietary counseling. Primary endpoint was the reduction of the fasting insulin/glucose ratio (HOMA index). Secondary endpoints 
included blood pressure, post-prandial glucose and insulin, lipids, and flow-mediated dilation (FMD).
Results:  HOMA index decreased significantly in the NC group compared with placebo (p < 0.05). Among secondary endpoints, a significant effect 
was shown on post-prandial glucose and insulin levels in the NC arm; a significant effect on total and LDL cholesterol levels was confirmed, as was 
the improvement in FMD. A significant reduction in systolic blood pressure levels was also noted in the NC group (p < 0.05).
Conclusions:  In a heterogeneous population of MS patients, a NC significantly reduced peripheral indices of insulin resistance, along with 
beneficial effects on lipid profile, endothelial function and blood pressure.
Patient characteristics at baseline and 18-weeks. p of change vs placebo
NC Baseline
n=29
NC 18-wk
P Baseline
(n=30)
P 18-wk p NC vs. P
Age (yr) - Sex (M%) 53±7 - 69% 50±11 - 60%
Waist circumference (cm) 110±9 108±9 115±13 114±13 ns
SBP (mmHg) 125±13 120±9 125±14 126±12 0,047
Fasting glucose (mmol/L) 5,72±1,22 5,28±1,11 4,72±0,67 4,55±0,67 ns
Fasting insulin (pmol/L) 90±42 76±42 90±69 111±90 0,042
HOMA-IR 3,2±1,5 2,6±1,3 2,7±2 3,2±2,6 0,023
HDL-C (mmol/L) 1,08±0,26 1,08±0,23 1,18±0,35 1,1±0,28 ns
LDL-C (mmol/L) 3,49±0,19 2,69±0,54 3,05±1 2,93±0,99 <0,001
FMD (%) 6,7±3 8,7±3,3 6,8±1,9 6,8±2 0,03
